Payment overview · 2025
General Payments
$758.76
39 reported records · 12 companies
Healthcare provider profile · identity verified
Amanda Heller Scott, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BATESBURG LEESVILLE, SC · NPI 1952801276
Verified facts
What the public records show
CMS Open Payments records show Amanda Heller Scott, PA-C received $758.76 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $197.33 | 26.0% | 10 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $174.30 | 23.0% | 11 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $116.86 | 15.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $89.04 | 11.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.16 | 4.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.69 | 4.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.18 | 3.2% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $23.35 | 3.1% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $18.93 | 2.5% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $15.90 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.87 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.15 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $758.76 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $174.30 | 11 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $174.30 | 11 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $174.30 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $117.79 | 5 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $116.86 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $96.56 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $89.04 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.90 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.69 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Morphine Sulfate Er | Morphine Sulfate | 196 | 50 |
| Gabapentin | Gabapentin | 121 | 37 |
| Oxycodone Hcl | Oxycodone Hcl | 113 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 103 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 56 |
| Oxycontin | Oxycodone Hcl | 96 | 17 |
| Pregabalin | Pregabalin | 88 | 22 |
| Lisinopril | Lisinopril | 86 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 26 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 71 | 16 |
| Famotidine | Famotidine | 70 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 23 |
| Clonazepam | Clonazepam | 59 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 58 | 25 |
| Ozempic | Semaglutide | 57 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 55 | 27 |
| Xtampza Er | Oxycodone Myristate | 52 | 19 |
| Metformin Hcl | Metformin Hcl | 48 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 19 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | 16 |
| Omeprazole | Omeprazole | 40 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 11 |
| Ondansetron Odt | Ondansetron | 37 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 14 |
| Alprazolam | Alprazolam | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | 18 |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Losartan Potassium | Losartan Potassium | 32 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 27 |
| Methadone Hcl | Methadone Hcl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 29 | 13 |
| Topiramate | Topiramate | 29 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | 11 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 22 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | 12 |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Furosemide | Furosemide | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $758.76 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dyanavel XR, FARXIGA, NALOCET, NURTEC ODT, Omnipod, Ozempic, PROLATE, REXULTI, SUBLOCADE, TANLOR, TRELEGY ELLIPTA, VRAYLAR, Xhance, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error